Loading…
Medifast, Inc. is projected to rise to $11.63 by 2027, a +8% move from its current price of $10.72. MED is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $10.55 | $10.73 | $10.91 | +0.07% |
| Jul 14 | $10.48 | $10.74 | $11.00 | +0.15% |
| Jul 15 | $10.43 | $10.74 | $11.06 | +0.22% |
| Jul 16 | $10.39 | $10.75 | $11.12 | +0.29% |
| Jul 17 | $10.36 | $10.76 | $11.18 | +0.36% |
| Jul 18 | $10.33 | $10.77 | $11.22 | +0.44% |
| Jul 19 | $10.30 | $10.77 | $11.27 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.30 | $10.77 | $11.27 | +0.51% |
| Week 2 | $10.16 | $10.83 | $11.54 | +1.02% |
| Week 3 | $10.07 | $10.89 | $11.77 | +1.54% |
| Week 4 | $10.00 | $10.94 | $11.97 | +2.06% |
| Week 5 | $9.94 | $11.00 | $12.16 | +2.58% |
| Week 6 | $9.90 | $11.05 | $12.34 | +3.10% |
| Week 7 | $9.86 | $11.11 | $12.51 | +3.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Medifast, Inc. operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address weight loss in the United States. It offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, essential amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements.
It also provides lifestyle plans consisting of 5 & 1 Plan and 5 & 1 ACTIVE Plan, which provides a targeted reset of the body's metabolism by activating strong and targeted fat burn; Optimal Weight 4 & 2 & 1 Plan and Optimal Weight 4 & 2 ACTIVE Plan, which is designed for clients who want to continue eating all food groups or want a flexible meal plan to achieve a healthy weight; OPTAVIA Optimization Plan, a personalized approach to help clients\' long-term weight management; and OPTAVIA GLP-1 Nutrition Support Plan, a nutritional companion to GLP-1 medication that allows clients to focus on weight loss without the stress of figuring out what to eat. In addition, the company offers metabolic synchronization, a science that reverses metabolic dysfunction through a targeted reset of the body's metabolism. It markets its products through point-of-sale transactions executed over an e-commerce platform.
The company serves health and wellness consumers. The company was formerly known as Healthrite, Inc. and changed its name to Medifast, Inc. in May 2001. Medifast, Inc. was incorporated in 1980 and is headquartered in Baltimore, Maryland.
Medifast, Inc. (MED) is a Consumer Cyclical stock currently trading at $10.36 with a market cap of $115.19M, and it sits at rank 4144. The stock is part of the Consumer Cyclical segment and is currently priced to reflect a near-term horizon that includes a neutral technical backdrop.
A major floor 21.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.9% below — buyers have tended to step in here.
The nearest ceiling, 22.7% above — a clean break opens room to run.
A major ceiling 33.5% above — clearing it would confirm fresh momentum.
Key MED support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MED market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.80 | Sell | $10.76 | Sell |
| MA 10 | $10.78 | Sell | $10.81 | Sell |
| MA 20 | $10.97 | Sell | $11.03 | Sell |
| MA 50 | $11.77 | Sell | $11.32 | Sell |
| MA 100 | $11.09 | Sell | $11.37 | Sell |
| MA 200 | $11.49 | Sell | $11.98 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.99 | Neutral |
| Stoch RSI (14) | 78.06 | Neutral |
| CCI (20) | -44.25 | Neutral |
| Williams %R (14) | -38.10 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 0.94 | Buy |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 61.90 | Neutral |
| TRIX (15) | -0.44 | Sell |
| Awesome (5,34) | -0.79 | Sell |
| Ultimate (7,14,28) | 48.49 | Neutral |
| Momentum (10) | 0.52 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 10.69 | Buy |
| ADX (14) | 23.10 | Sell |
| ATR (14) | 0.17 | Info |
Near-term technical picture shows NEUTRAL sentiment with RSI 14 of 20. The price trades below both the SMA50 ($11.81) and the SMA200 ($11.67), suggesting modest momentum around current levels. Support is at $10.36 and resistance at $13.15, framing a 30-day range of $9.15 to $11.73. The volatility backdrop is elevated, with annualized volatility at 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.53 | $10.72 | $14.26 | 0% | Neutral | |
| $9.52 | $11.63 | $14.84 | +8% | Neutral | |
| $9.80 | $12.19 | $15.99 | +14% | Neutral | |
| $10.81 | $13.66 | $18.29 | +27% | Bullish | |
| $10.62 | $13.60 | $18.54 | +27% | Bullish | |
| $12.20 | $15.81 | $21.90 | +48% | Bullish | |
| $14.46 | $18.94 | $26.61 | +77% | Bullish | |
| $14.71 | $19.48 | $27.72 | +82% | Bullish | |
| $15.59 | $20.85 | $30.01 | +94% | Bullish | |
| $15.67 | $21.15 | $30.79 | +97% | Bullish | |
| $22.96 | $32.33 | $49.32 | +202% | Bullish | |
| $36.23 | $54.72 | $89.47 | +410% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.53 | $10.72 | $12.90 | +0.00% |
| August 2026 | $9.70 | $11.36 | $13.59 | +5.97% |
| September 2026 | $9.74 | $11.46 | $13.81 | +0.84% |
| October 2026 | $9.61 | $11.35 | $13.77 | -0.92% |
| November 2026 | $9.72 | $11.52 | $14.06 | +1.51% |
| December 2026 | $9.78 | $11.63 | $14.26 | +0.92% |
Click any year to see its month-by-month MED forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MED is projected to trade between $9.53 and $14.26, averaging $10.72 — a potential gain of 0% from today's $10.72. A consolidation phase looks the most probable path here.
Medifast, Inc.'s 2027 outlook centres on $11.63, within a $9.52 to $14.84 range. That is up +8% on the projected 2026 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2028, MED could reach as high as $15.99, with a base case around $12.19 and support toward $9.80 — roughly +14% from $10.72. A consolidation phase looks the most probable path here.
Expect MED to range from $10.81 to $18.29 through 2029. The $13.66 average target implies a +27% move from current prices. That is up +12% on the projected 2028 average. Momentum favours further upside here.
The MED price prediction for 2030 points to an average of $13.60 (low $10.62, high $18.54) — a potential gain of +27% on today's $10.72. Buyers look set to stay in control over this stretch.
In 2031, MED is projected to trade between $12.20 and $21.90, averaging $15.81 — a potential gain of +48% from today's $10.72. That is up +16% on the projected 2030 average. Momentum favours further upside here.
Medifast, Inc.'s 2032 outlook centres on $18.94, within a $14.46 to $26.61 range. That is up +20% on the projected 2031 average. That marks a +77% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MED could reach as high as $27.72, with a base case around $19.48 and support toward $14.71 — roughly +82% from $10.72. Momentum favours further upside here.
Expect MED to range from $15.59 to $30.01 through 2034. The $20.85 average target implies a +94% move from current prices. That is up +7% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MED price prediction for 2035 points to an average of $21.15 (low $15.67, high $30.79) — a potential gain of +97% on today's $10.72. Momentum favours further upside here.
In 2040, MED is projected to trade between $22.96 and $49.32, averaging $32.33 — a potential gain of +202% from today's $10.72. That is up +53% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Medifast, Inc.'s 2050 outlook centres on $54.72, within a $36.23 to $89.47 range. That is up +69% on the projected 2040 average. That marks a +410% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MED today (≈ 93.283582 MED) could be worth
$5,104.41
+$4,104.41 (+410%) by 2050 · US Dollar
Based on the average projected MED price of $54.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MEDwould be worth at today's price.
$1,000 invested in MED on Jul 10, 2025 (≈ 68.11989 MED) would be worth
$730.25
-$269.75 (-27.0%) today · 0.73× · US Dollar
Based on a MED entry price of $14.68 vs. today's $10.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.96 | $978.1 | -2.2% |
| 1 month ago | $12.14 | $883.03 | -11.7% |
| 3 months ago | $10.06 | $1,065.61 | +6.6% |
| 6 months ago | $11.69 | $917.02 | -8.3% |
| 1 year ago | $14.68 | $730.25 | -27.0% |
| All time (5.0y) ago | $276.57 | $38.76 | -96.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MED forecast.
Our base-case forecast reaches $21.00 around 2035.
Implied market cap at $21.00: $233.5M
Longer-horizon forecasts depict a bullish trajectory with gradual price appreciation. The 2026–2029 average prices range from $10.36 to $12.66, with maxs up to $16.97 and ROIs climbing from 0% toward higher levels. By 2030, the average is projected at $12.50 with a max of $17.05 and ROI of 20.6%.
The forecasts expand markedly by 2040 to an average of $29.08 with a max of $44.39 and an ROI of 180.7%, and by 2050 to an average of $46.63 with a max of $76.31 and an ROI of 350.1%. Sentiment shifts from NEUTRAL in the nearer term to BULLISH from 2029 onward. The path implies meaningful upside potential, tempered by the usual uncertainty and market risk that can affect outcomes.
Tap a question to reveal the answer.
Avg $12.50, Min $9.75, Max $17.05; ROI 20.6%; Sentiment BULLISH.
Forecasts show a bullish long-term trajectory, with Avg prices rising to $12.50 in 2030 and reaching $46.63 by 2050, with a max of $76.31 and ROIs of 20.6% (2030), 180.7% (2040), and 350.1% (2050). These are estimates, not guarantees.
Yes—the max forecast by 2050 is $76.31, so reaching $50 is within the long-term forecast.
Low $9.15, High $11.73.
Medifast, Inc. Community Discussion
0Share your Medifast, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.